综述:肝硬化腹水与急性肾损伤管理的最新进展
本文通过检索Pubmed英文文献,综述肝硬化腹水及肝肾综合征-急性肾损伤(HRS-AKI)管理的最新进展。药物方面包括更早治疗临床显著门静脉高压以延迟腹水出现、使用人血白蛋白减轻全身炎症,以及钠-葡萄糖共转运蛋白2等新药和血管加压素部分激动剂、松弛素等正在研究;介入方面包括TIPS技术改进与患者选择、alfa泵系统及长期姑息性腹腔引流。结论认为新策略改善了预后,未来需大型多中心临床试验确认。
要点
- 更早治疗临床显著门静脉高压可延迟腹水出现,人血白蛋白可减轻全身炎症。
- 钠-葡萄糖共转运蛋白2抑制剂正在肝硬化腹水患者中研究。
- 血管加压素部分激动剂和松弛素正在HRS-AKI中研究。
核心结论
- 基于对腹水和HRS-AKI病理生理的更好理解,新治疗策略已在这些患者中显示改善预后。
- 未来许多方法将在大型多中心临床试验中得到确认,以造福腹水和HRS-AKI患者。
研究设计与样本
- 综述类文章,在Pubmed以cirrhosis、ascites、renal dysfunction、acute kidney injury、hepatorenal syndrome、beta-blockers、albumin、TIPS和vasoconstrictors为关键词检索,仅纳入英文文献。
主要发现
- 更早治疗临床显著门静脉高压可延迟腹水出现,人血白蛋白溶液可减轻全身炎症从而改善肝硬化相关血流动力学变化。
- 钠-葡萄糖共转运蛋白2等新类别药物正在肝硬化腹水患者中研究。
- HRS-AKI管理方面,血管加压素部分激动剂和松弛素等新药正在研究中。
- 介入进展包括TIPS技术改进和患者选择优化以改善难治性腹水结局。
- alfa泵系统的开发及长期姑息性腹腔引流结局研究将有助于改善难治性腹水患者生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Better understanding of disease pathophysiology has led to advances in managing ascites and its associated complications including hepatorenal syndrome-acute kidney Injury (HRS-AKI), especially medicinal and interventional advances. AIM: To review the latest changes in the management of ascites and HRS-AKI. METHODS: A literature search was conducted in Pubmed, using the keywords cirrhosis, ascites, renal dysfunction, acute kidney injury, hepatorenal syndrome, beta-blockers, albumin, TIPS and vasoconstrictors, including only publications in English. RESULTS: The medicinal advances include earlier treatment of clinically significant portal hypertension to delay the onset of ascites and the use of human albumin solution to attenuate systemic inflammation thus improving the haemodynamic changes associated with cirrhosis. Furthermore, new classes of drugs such as sodium glucose co-transporter 2 are being investigated for use in patients with cirrhosis and ascites. For HRS-AKI management, newer pharmacological agents such as vasopressin partial agonists and relaxin are being studied. Interventional advances include the refinement of TIPS technique and patient selection to improve outcomes in patients with refractory ascites. The development of the alfa pump system and the study of outcomes associated with the use of long-term palliative abdominal drain will also serve to improve the quality of life in patients with refractory ascites. CONCLUSIONS: New treatment strategies emerged from better understanding of the pathophysiology of ascites and HRS-AKI have shown improved prognosis in these patients. The future will see many of these approaches confirmed in large multi-centre clinical trials with the aim to benefit the patients with ascites and HRS-AKI.
引用
- Adebayo D, Wong F. Review article: Recent advances in ascites and acute kidney injury management in cirrhosis. Aliment Pharmacol Ther. 2024. PMID: 38526023. doi:10.1111/apt.17972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。